

Esther I Verhoef

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3704607/publications.pdf>

Version: 2024-02-01

33
papers

1,125
citations

430874

18
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

1774
citing authors

#	ARTICLE	IF	CITATIONS
1	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. <i>Modern Pathology</i> , 2021, 34, 184-193.	5.5	32
2	Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. <i>Modern Pathology</i> , 2021, 34, 2064-2070.	5.5	10
3	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. <i>European Urology</i> , 2020, 77, 191-198.	1.9	57
4	Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 991-996.	2.5	1
5	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 191-197.	3.7	20
6	Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. <i>Histopathology</i> , 2020, 77, 850-861.	2.9	24
7	Clinicopathological characteristics of glomeruloid architecture in prostate cancer. <i>Modern Pathology</i> , 2020, 33, 1618-1625.	5.5	11
8	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. <i>Histopathology</i> , 2020, 76, 755-762.	2.9	18
9	Combined transmission, dark field and fluorescence microscopy for intact, 3D tissue analysis of biopsies. <i>Journal of Biomedical Optics</i> , 2020, 25, .	2.6	1
10	Combined transmission, dark field and fluorescence microscopy for intact, 3D tissue analysis of biopsies. <i>Journal of Biomedical Optics</i> , 2020, 25, .	2.6	3
11	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. <i>Cancers</i> , 2019, 11, 1062.	3.7	9
12	Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. <i>Prostate</i> , 2019, 79, 1032-1042.	2.3	10
13	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. <i>Histopathology</i> , 2019, 75, 338-345.	2.9	22
14	Three-dimensional architecture of common benign and precancerous prostate epithelial lesions. <i>Histopathology</i> , 2019, 74, 1036-1044.	2.9	11
15	Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. <i>Modern Pathology</i> , 2019, 32, 1032-1041.	5.5	30
16	Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. <i>Modern Pathology</i> , 2019, 32, 139-146.	5.5	71
17	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 471-482.	3.1	17
18	Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model. <i>EBioMedicine</i> , 2018, 27, 182-186.	6.1	11

#	ARTICLE	IF	CITATIONS
19	Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3+4=7 and highest Gleason score 3+4=7 or >3+4=7. <i>Histopathology</i> , 2018, 72, 760-765.	2.9	14
20	Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. <i>Cancer Research</i> , 2018, 78, 4671-4679.	0.9	41
21	Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. <i>Oncotarget</i> , 2018, 9, 36444-36456.	1.8	10
22	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
23	Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. <i>Modern Pathology</i> , 2016, 29, 630-636.	5.5	174
24	Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. <i>European Journal of Cancer</i> , 2016, 66, 26-33.	2.8	66
25	Three-dimensional microscopic analysis of clinical prostate specimens. <i>Histopathology</i> , 2016, 69, 985-992.	2.9	71
26	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. <i>Oncotarget</i> , 2016, 7, 70669-70684.	1.8	21
27	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 13167-13181.	1.8	14
28	MET expression during prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 31029-31036.	1.8	18
29	Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. <i>Oncotarget</i> , 2016, 7, 37846-37856.	1.8	14
30	SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 230-240.	0.9	61
31	Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. <i>Oncotarget</i> , 2015, 6, 4036-4050.	1.8	42
32	Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. <i>Oncotarget</i> , 2015, 6, 24488-24498.	1.8	42
33	Validation of stem cell markers in clinical prostate cancer: $\alpha 6$ -Integrin is predictive for non-aggressive disease. <i>Prostate</i> , 2014, 74, 488-496.	2.3	37